NCT04467541View on ClinicalTrials.gov

Safety & Immunogenicity of Enterovirus Type 71 Vaccine in Healthy Adults and Children 6-71months

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

430

Participants

Timeline

Start Date

December 24, 2019

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions

Hand Foot & Mouth Disease

Interventions

BIOLOGICAL

Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell)

Inactivated Enterovirus Type 71 (EV71) Vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months

Trial Locations (1)

1000

Icddr,B, Dhaka

All Listed Sponsors

lead

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

NCT04467541 - Safety & Immunogenicity of Enterovirus Type 71 Vaccine in Healthy Adults and Children 6-71months | Biotech Hunter | Biotech Hunter